Claim your FREE trial subscription!
Prescription Medicines:
Research & Development in the Pharmaceutical Industry: Options for Success (report)
Urch Publishing
Management Report February 2004
The pharmaceutical industry is one of the most successful industries in the technology sector and its ability to innovate has seen it launch nearly 1,400 new chemical entities as human therapeutics over the last 30 years.
Despite this success, the environment in which the industry operates is becoming more competitive and the research and development (R&D) process to bring a drug successfully to market remains challenging. Drug development is a risky and expensive process and involves combining scientific excellence with a thorough understanding of the business environment.
Research & Development in the Pharmaceutical Industry - Options for success is a unique report that provides the latest information and insight into pharmaceutical industry research and development issues. This report analyses the key issues affecting a pharmaceutical company’s success in the search for and development of new drugs.
Chapter 1: A Background to Pharmaceutical R&D
Productivity of the global industry
Case study: productivity of the Japanese pharmaceutical industry
Drug development innovation
Intellectual property
Reducing development times
Success rates
The in silico approach to drug development
Case study: Nippon Kayaku and NEC collaboration in cancer research
Case study: Pharsight
R&D commitment and risk assessment
Case study: Bioglan Pharma
Case study: Scotia Holdings
Clinical trials
Chapter 2: Strategies and Planning for Pharmaceutical R&D
Therapeutic area focus
Osteoporosis
CNS disorders
Pharmacoeconomics
Models of R&D
Organisational structure
An industry under pressure
A growing trend
The disadvantages of merging
Alternatives to mergers?
The Pfizer-Pharmacia merger
The Amgen-Immunex merger
Chapter 3: Improving the Environment for Drug Development
Regulatory strategy
The Georgetown conference on drug development issues
The FDA's aim to reduce the time and costs involved in drug development
The ICH E5 guideline
Chapter 4: Pharmaceutical R&D and the Generics Industry
The generics industry
The growth of the market for pharmaceutical generics
Protection of the brand in the face of generic competition
Generic competition and R&D innovation
Lilly's year X strategy
Generics manufacturers and mainstream R&D
Teva
The Indian pharmaceutical industry
Mainstream pharmaceutical companies and generics
The opportunity for biogenerics
Impending biogeneric patent battles
Case study: biogeneric competition to Epogen
Outlook for biogenerics
Pharmaceutical R&D and public perceptions
Chapter 5: Using External Parties for Drug Development - Biotechnology,Drug Delivery Technologies and Outsourcing
Licensing and joint research
The potential of biotech
Companies involved in biotech research
Biotech company corporate culture
Biotech R&D
Financing biotech R&D
Case study: Genentech
Biotechnology at a European level
Consolidation in the Swedish biotech industry
Biotechnology in Japan
Drug delivery systems
The future of the drug delivery industry
Outsourcing
Case study: virtual pharmaceutical companies
Chapter 6: Pharmaceutical R&D Location and Staffing
Japan as a location for R&D
The importance of staff
Employment in the European pharmaceutical industry
Employment in the UK pharmaceutical industry
Employment in the German pharmaceutical industry
Employment in the French pharmaceutical industry
Employment in the Swiss pharmaceutical industry
Employment in the Japanese pharmaceutical industry
Recruiting staff
Retaining staff
The impact of staff losses
Looking outside the pharmaceutical and biotech industries for staff
Government incentives for the pharmaceutical industry
References
List of Figures
Figure 1.2 New drug substances by country of origin
Figure 1.3 R&D of the Japanese pharmaceutical industry
Figure 1.4 Number of NMEs launched globally, 1992-2002
Figure 1.5 Analysis of active drug clinical trials by therapeutic category: active INDs (commercial) for year-end 2001
Figure 2.1 US Pharma R&D investment by therapeutic area
Figure 2.2 Population projections for 2000 and 2020 - percentage of the population aged 65 years or over
Figure 2.3 The impact of osteoporosis in Europe: hospital costs for osteoporosis-related hip fracture
Figure 4.1 Average approval time for generic drugs, according to the FDA
Figure 4.2 Estimated European generics market by volume, 2000
Figure 4.3 Sales for major Lilly drugs, 2002
Figure 4.4 Top-selling biotech products, 2001/02
Figure 5.1 New US biotech drug and vaccine approvals/new indication approvals by year
Figure 5.2 Global biotech R&D, 1990-2000
Figure 5.3 Global split of biotech R&D
Figure 5.4 Worldwide spending on CRO services
Figure 6.1 R&D expenditure by pharmaceutical companies in the US and Europe
Figure 6.2 Japanese pharmaceutical company sales, 2001
Figure 6.3 Employment in the US pharmaceutical industry
Figure 6.4 Employment in the European pharmaceutical industry
Figure 6.5 Pharmaceutical output in Europe, Japan and the US
Figure 6.6 Pharmaceutical R&D in the UK
List of Tables
Table 3.1 Ethnic factors as defined by the ICH E5 guideline
Table 6.1 Approaches to recruiting and retaining staff
For full details, please email jenniferc@cmsinfo.com
CMS, P&A House, Alma Road, Chesham, Bucks. HP5 3HB, UK
Tel: +44 (0)1494 771734
Fax: +44 (0)1494 778994
e-mail: Jennifer Cowlard
copyright © 2008 all rights reserved
For more information about us, visit CMSinfo.
